Voutilainen lab studies the CDNF/MANF family of neurotrophic factors and GDNF family ligands. The focus of research is mainly on two major diseases, amyotrophic lateral sclerosis (ALS) and Parkinson's disease, with the aim of finding neurorestorative treatments that promote functional recovery from these diseases. Our most promising current candidate for ALS and PD is cerebral dopamine neurotrophic factor, CDNF, which promotes neuronal survival and growth. In 2017, CDNF moved on to clinical trials for PD in Finland and Sweden. It has the potential to be the basis of a treatment strategy which could stop disease progression.